Volume 130, Issue 17

Cover Figure: Cooperation between NPM1 mutations and FLT3 and NRAS gene mutations generates diverse patterns and phenotypes of AML. See the article by Dovey et al.

WASHINGTON, October 26, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide
Harrison et al report the results of the first randomized trial comparing the first-in-class JAK1/2 inhibitor ruxolitinib with the best available therapy in patients with essential thrombocythemia (ET) that is resistant or intolerant to hydroxycarbamide.

TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
This work identifies a high-risk subset of patients with mantle cell lymphoma with no beneficial outcome after modern, cytarabine-based induction therapy and autologous stem cell transplantation.

CD207+CD1a+ cells circulate in pediatric patients with active Langerhans cell histiocytosis
Langerhans cell histiocytosis (LCH) is a disorder that is characterized by the pathologic accumulation of immature Langerhans cells and inflammatory cells in various organs. This paper reports that CD207+CD1a+ circulating cells are selectively increased in the peripheral blood of children with active LCH, as compared to those with non-active LCH.

The potential for chemotherapy-free strategies in mantle cell lymphoma
This Perspective from experts in the field highlights recent advances in chemotherapy-free strategies for mantle cell lymphoma.

Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
This article presents preclinical studies on the novel role and mechanism of function of eltrombopag as an iron chelator.


This week's complete table of contents

Why Submit to Blood?



Blood (, the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.